Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Regulatory / Erasca securities class action lawsuit
Regulatory securities class action

Erasca securities class action lawsuit

Analysis based on 6 articles · First reported Jul 15, 2026 · Last updated Jul 16, 2026

Sentiment
-40
Attention
3
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Erasca's stock price collapsed 53.9% upon disclosure of the alleged misconduct, erasing significant market value. The lawsuit may lead to substantial financial penalties and reputational damage for Erasca, affecting investor confidence in the biotech sector.

Biotechnology Pharmaceuticals
Event Summary

A securities class action lawsuit has been filed against Erasca (Nasdaq: ERAS) by Levi & Korsinsky, LLP on behalf of investors who purchased Erasca securities between January 14, 2025 and April 26, 2026. The complaint alleges that Erasca made false and misleading statements regarding its lead drug candidate ERAS-0015, including improper preclinical comparisons to Revolution Medicines' RMC-6236, and concealed patent infringement risks and a patient death. Erasca raised approximately $258.8 million in a January 2026 stock offering. When the truth was revealed, Erasca shares collapsed 53.9%. The lead plaintiff deadline is August 10, 2026.

Key Actions
100 Levi & Korsinsky filed class action Erasca
90 Erasca disclosed letter Revolution Medicines
85 Erasca disclosed patient death
80 Erasca announced public offering
70 Erasca acknowledged limited comparisons
Entities Involved
stock
Erasca
Erasca is the defendant in the securities class action lawsuit, accused of securities fraud. The company's stock price dropped 53.9% and it faces potential liability for alleged misstatements in its offering documents.
Importance 100.0 Sentiment -80.0
priv
Levi & Korsinsky
Levi & Korsinsky is the law firm that filed the class action lawsuit on behalf of investors. The firm is seeking lead plaintiff status and stands to gain legal fees if the case succeeds.
Importance 60.0 Sentiment 10.0
stock
Revolution Medicines
Revolution Medicines is the company whose drug RMC-6236 was allegedly improperly compared to Erasca's ERAS-0015. Erasca's alleged patent infringement of RevMed's patent may strengthen RevMed's competitive position.
Importance 50.0 Sentiment 20.0
govactor
United States — United States Securities and Exchange Commission
The SEC is the regulatory body that declared Erasca's shelf registration statement effective. The lawsuit alleges violations of SEC rules, and the SEC may investigate further.
Importance 40.0 Sentiment 0.0
per
Joseph E. Levi
Joseph E. Levi is a partner at Levi & Korsinsky and the contact attorney for the lawsuit. His role is to represent investors and seek recovery.
Importance 30.0 Sentiment 5.0
exch
Nasdaq
Nasdaq is the exchange where Erasca's stock is listed. The stock price decline and lawsuit may affect trading but Nasdaq itself is not directly impacted.
Importance 10.0 Sentiment 0.0
Relationships
Erasca competitor ↔ Revolution Medicines Erasca is a clinical-stage oncology company that directly competes with Revolution Medicines in developing pan-RAS molec
Levi & Korsinsky related ↔ United States — United States Securities and Exchange Commission
Levi & Korsinsky related ↔ Joseph E. Levi
United States — United States Securities and Exchange Commission related ↔ Joseph E. Levi
United States — United States Securities and Exchange Commission related ↔ Nasdaq
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.